Drug development

#AI #Drug development #Drug discovery #Machine learning #Therapeutics

Why we are on the cusp of a golden age of medicine 

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find out why he… Read More

#Cancer Research #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Collaboration #Drug candidates #Drug development #Drug discovery

Call for application: AI for antibody design 

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.  The chosen AION Labs startup… Read More

#News

#Drug development #Drug therapy

Oral GnRH antagonist licenced for treatment of uterine fibroids

Gedeon Richter has been granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA) for relugolix combination therapy (Ryeqo), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.   The decision reportedly makes the relugolix combination therapy the first oral gonadotropin-releasing hormone… Read More

#News

#AI / data analytics / healthtech / informatics #Biosciences #Drug development #Therapeutics

Analytical challenges when characterising complex molecules

Michael-John O’Connor, Director of Biochemical Services at BioPharmaSpec, discusses analysing biosimilars, glycosylated mAbs and PEGylated proteins with Lu Rahman.  LR: Outline the importance of bio-molecules in drug discovery. What is their potential within therapeutic development?    MJOC: The FDA’s recent approval of Biocon’s Semglee (long acting Insulin glargine) is the first example of an interchangeable biosimilar that can be substituted… Read More

#Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Drug design #Drug development #Drug discovery

AI round-up: the expanding influence of AI in drug discovery 

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They say the potential for… Read More

#Editor's Choice #Exclusive Content #News

#Drug development #Drug discovery #Drug targets #Protein chemistry / Proteomics #Research

Trivalent PROTACs more potent in targeted protein degradation 

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation. The research is published in Nature Chemical Biology.  Targeted protein degradation is an area of chemical biology that is said to be revolutionising drug discovery. It involves… Read More

#News

#Collaboration #Drug development

Ferrer and Treeway collaborate to develop treatment for ALS

Ferrer and Treeway have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis (ALS) in certain territories, including Europe and some Asian countries.   Ferrer is responsible for advancing the development and commercialisation of the product and will make royalty payments to Treeway at certain milestones. The deal… Read More

#News

#Collaboration #Drug development #Drug discovery #Research

This week in drug discovery (11-15 October) 

News round-up by DDW’s Megan Thomas for 11-15 October   For this week’s drug discovery round up, DDW’s Megan Thomas has selected five stories that showcase how organisations and collaboration within the drug discovery industry can provide researchers and drug developers with the tools they need to move forward with… Read More

#News

#Antibodies #Covid-19 #Drug development #Drug discovery #Preclinical development #Therapeutics

Highlights of Carterra’s Bamlanivimab story

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#Covid-19 #Drug development #Pharmaceuticals #R&D

Pharmaceutical industry warned not to undo pandemic advances 

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online… Read More

#News

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News